Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis

Metabolism: Clinical and Experimental

Volumn 63, Issue 8, 2014, Pages 1041-1048

  Lee, Jinmi ^a   Hong, Seok Woo ^a   Park, Se Eun ^a   Rhee, Eun Jung ^a   Park, Cheol Young ^a   Oh, Ki Won ^a   Park, Sung Woo ^a   Lee, Won Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Exendin 4; Fatty acid oxidation; FGF21; FGFRs; SIRT1

Indexed keywords

EXENDIN 4; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MESSENGER RNA; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIRTUIN 1; SMALL INTERFERING RNA; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; HEPG2 CELL LINE; IN VITRO STUDY; LIPID DIET; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIVER CELL; LOW FAT DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EXENDIN-4; FATTY ACID OXIDATION; FGF21; FGFRS; SIRT1;

ANIMALS; BLOTTING, WESTERN; CELL LINE; FIBROBLAST GROWTH FACTORS; HUMANS; LIPID METABOLISM; MICE; MICE, INBRED C57BL; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; SIRTUIN 1; VENOMS;

EID: 84904399681     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.04.011     Document Type: Article

References (44)

1. A. Kharitonenkov FGFs and metabolism Curr Opin Pharmacol 9 6 2009 805 810
2. H. Kurosu, and M. Kuro-o Endocrine fibroblast growth factors as regulators of metabolic homeostasis Biofactors 35 1 2009 52 60
3. T. Lundåsen, M.C. Hunt, and L.M. Nilsson et al. Pparα is a key regulator of hepatic FGF21 Biochem Biophys Res Commun 360 2 2007 437 440 (Pubitemid 47039157)
4. H. Kim, R. Mendez, and Z. Zheng et al. Liver-enriched transcription factor crebh interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21 Endocrinology 155 3 2014 769 782
5. D. Cuevas-Ramos, P. Almeda-Valdes, and C.A. Aguilar-Salinas et al. The role of fibroblast growth factor 21 (FGF21) on energy balance, glucose and lipid metabolism Curr Diabetes Rev 5 4 2009 216 220
6. A. Kharitonenkov, T.L. Shiyanova, and A. Koester et al. FGF-21 as a novel metabolic regulator J Clin Invest 115 6 2005 1627 1635 (Pubitemid 40814671)
7. C. Wang, J. Dai, and M. Yang et al. Silencing of FGF-21 expression promotes hepatic gluconeogenesis and glycogenolysis by regulation of stat3-socs3 signal FEBS J 281 9 2014 2136 2147
8. J. Xu, D.J. Lloyd, and C. Hale et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice Diabetes 58 1 2009 250 259
9. A. Vassilopoulos, K.S. Fritz, and D.R. Petersen et al. The human sirtuin family: Evolutionary divergences and functions Hum Genomics 5 5 2011 485 496
10. S. Michan, and D. Sinclair Sirtuins in mammals: Insights into their biological function Biochem J 404 1 2007 1 13 (Pubitemid 46788079)
11. A. Purushotham, T.T. Schug, and Q. Xu et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation Cell Metab 9 4 2009 327 338
12. A.Z. Caron, X. He, and W. Mottawea et al. The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome FASEB J 28 3 2014 1306 1316
13. J. Lee, S.W. Hong, and S.W. Chae et al. Exendin-4 improves steatohepatitis by increasing sirt1 expression in high-fat diet-induced obese C57BL/6J mice PLoS One 7 2 2012 e31394
14. H.S. Kim, C. Xiao, and R.H. Wang et al. Hepatic-specific disruption of sirt6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis Cell Metab 12 3 2010 224 236
15. S.J. Yang, J.M. Choi, and S.W. Chae et al. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats PLoS One 6 2 2011 e17057
16. D.M. Van Rooyen, C.Z. Larter, and W.G. Haigh et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis Gastroenterology 141 4 2011 1393 1403
17. N.C. Leite, G.F. Salles, and A.L.E. Araujo et al. Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type2 diabetes mellitus Liver Int 29 1 2008 113 119
18. H. Misu, K. Ishikura, and S. Kurita et al. Inverse correlation between serum levels of selenoprotein p and adiponectin in patients with type 2 diabetes PLoS One 7 4 2012 e34952
19. H. Misu, T. Takamura, and H. Takayama et al. A liver-derived secretory protein, selenoprotein p, causes insulin resistance Cell Metab 12 5 2010 483 495
20. Y. Zhao, J.D. Dunbar, and A. Kharitonenkov FGF21 as a therapeutic reagent Adv Exp Med Biol 2012 214 228
21. J.P. Camporez, F.R. Jornayvaz, and M.C. Petersen et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice Endocrinology 154 9 2013 3099 3109
22. M. Suzuki, Y. Uehara, and K. Motomura-Matsuzaka et al. Βklotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c Mol Endocrinol 22 4 2008 1006 1014 (Pubitemid 351482834)
23. H. Kurosu, M. Choi, and Y. Ogawa et al. Tissue-specific expression of βklotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 J Biol Chem 282 37 2007 26687 26695 (Pubitemid 47501965)
24. X. Ge, Y. Wang, and K.S. Lam et al. Metabolic actions of FGF21: Molecular mechanisms and therapeutic implications Acta Pharm Sin B 2 4 2012 350 357
25. M.J. Jurynec, and D.J. Grunwald SHIP2, a factor associated with diet-induced obesity and insulin sensitivity, attenuates FGF signaling in vivo Dis Model Mech 3 11-12 2010 733 742
26. M.J. Potthoff, T. Inagaki, and S. Satapati et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response Proc Natl Acad Sci U S A 106 26 2009 10853 10858
27. E.B. Nygaard, S.G. Vienberg, and C. ∅rskov et al. Metformin stimulates FGF21 expression in primary hepatocytes Exp Diabetes Res 2012 2012 465282
28. S. Samson, P. Sathyanarayana, and M. Jogi et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial Diabetologia 54 12 2011 3093 3100
29. X. Zhang, D.C.Y. Yeung, and M. Karpisek et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans Diabetes 57 5 2008 1246 1253
30. P.C. Chui, P.J. Antonellis, and H.A. Bina et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state Diabetes 59 11 2010 2781 2789
31. J. Dushay, P.C. Chui, and G.S. Gopalakrishnan et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease Gastroenterology 139 2 2010 456 463
32. K. Mai, F. Schwarz, and T. Bobbert et al. Relation between fibroblast growth factor-21, adiposity, metabolism, and weight reduction Metabolism 60 2 2011 306 311
33. T. Reinehr, J. Woelfle, and R. Wunsch et al. Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: A longitudinal analysis J Clin Endocrinol Metab 97 6 2012 2143 2150
34. Z.Q. Wang, X.H. Zhang, and Y. Yu et al. Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and ampk signaling independently of FGF21 pathway Metabolism 62 9 2013 1239 1249
35. M. Yang, L. Zhang, and C. Wang et al. Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance PLoS One 7 11 2012 e48392
36. M.S. Lee, S.E. Choi, and E.S. Ha et al. Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-kB Metabolism 61 8 2012 1142 1151
37. S.L. Zhu, Z.Y. Zhang, and G.P. Ren et al. Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism Yao Xue Xue Bao 48 12 2013 1778 1784
38. X. Hou, S. Xu, and K.A. Maitland-Toolan et al. Sirt1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase J Biol Chem 283 29 2008 20015 20026
39. P.W. Caton, N.K. Nayuni, and J. Kieswich et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5 J Endocrinol 205 1 2010 97 106
40. J.E. Dominy Jr., Y. Lee, and M.P. Jedrychowski et al. The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis Mol Cell 48 6 2012 900 913
41. Z. Gerhart-Hines, J.E. Dominy Jr., and S.M. Blattler et al. The cAMP/PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation independently of changes in NAD(+) Mol Cell 44 6 2011 851 863
42. J.T. Rodgers, C. Lerin, and W. Haas et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1 Nature 434 7029 2005 113 118 (Pubitemid 40349395)
43. R.H. Wang, H.S. Kim, and C. Xiao et al. Hepatic sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance J Clin Invest 121 11 2011 4477 4490
44. A. Labbé, C. Garand, and V.C. Cogger et al. Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome J Gerontol A Biol Sci Med Sci 66 3 2011 264 278